Accessibility Menu
Bioxytran logo

Bioxytran

(OTC) BIXT

Current Price$0.03
Market Cap$2.81M
Since IPO (2018)-91%
5 Year+12,900%
1 Year-75%
1 Month-18%

Bioxytran Financials at a Glance

Market Cap

$2.81M

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.84M

EPS (TTM)

-$0.03

P/E Ratio

-1.08

Dividend

$0.00

Beta (Volatility)

-0.93 (Low)

Price

$0.03

Volume

36,097

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.03

52-Week Range

$0.03 - $0.11

Estimated Earnings Date

Apr 15, 2026

BIXT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bioxytran

Industry

Biotechnology

Employees

2

CEO

David Platt, PhD

Headquarters

Newton, MA 02464, US

BIXT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

90.64%

Return on Capital

N/A

Return on Assets

-461.34%

Earnings Yield

-92.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.81M

Shares Outstanding

98.90M

Volume

36.10K

Avg. Volume

94.04K

Financials (TTM)

Gross Profit

-$11.80K

Operating Income

-$3.27M

EBITDA

-$2.46M

Operating Cash Flow

-$597.74K

Capital Expenditure

-$24.39K

Free Cash Flow

-$622.13K

Cash & ST Invst.

$463.05K

Total Debt

$1.21M

Bioxytran Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.11K

-13.9%

Gross Margin

0.00%

N/A

Market Cap

$2.81M

N/A

Market Cap/Employee

$936.23K

N/A

Employees

3

N/A

Net Income

-$2.07M

-52.8%

EBITDA

-$1.93M

-46.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$463.05K

+10549.7%

Total Debt

$1.21M

-4.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.21M

-4.0%

Return on Assets

-4.61%

N/A

Return on Invested Capital

74.45%

N/A

Free Cash Flow

-$247.84K

-48.1%

Operating Cash Flow

-$238.61K

-42.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BVAXFBioVaxys Technology Corp.
$0.09-32.47%
KNBIFKane Biotech Inc.
$0.02+7.11%
BZYRBurzynski Research Institute, Inc.
$0.01-10.00%
THERTheralink Technologies, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CMCSAComcast
$24.22+0.05%
AALAmerican Airlines Group
$17.92+0.00%
SMCISuper Micro Computer
$28.15-0.08%
TAT&T
$21.82-0.04%

Questions About BIXT

What is the current price of Bioxytran?

Bioxytran is trading at $0.03 per share.

What is the 52-week range for Bioxytran?

Over the past 52 weeks, Bioxytran has traded between $0.03 and $0.11.

How much debt does Bioxytran have?

As of the most recent reporting period, Bioxytran reported total debt of $1.21M.

How much cash does Bioxytran have on hand?

Bioxytran reported $463.05K in cash and cash equivalents in its most recent financial results.

What is Bioxytran’s dividend yield?

Bioxytran does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.